Platelet Reactivity of Aspirin and Clopidogrel in Coronary Artery Disease Patients with or Without Diabetes Mellitus

Suharjono and Wahyudi E. D. and Yunita A. and Yogiarto M. and Zulkarnain B. S. (2016) Platelet Reactivity of Aspirin and Clopidogrel in Coronary Artery Disease Patients with or Without Diabetes Mellitus. International Journal of Pharmacy and Pharmaceutical Sciences, 8 (7). pp. 690-694. ISSN International Journal of Pharmacy and Pharmaceutical Sciences

[img] Text (FULLTEXT)
BUKTI C-7 IJPCR,Vol8,Issue7,Article9 SUHARJONO CPG ASPIRIN.pdf
Restricted to Registered users only

Download (412kB) | Request a copy
[img] Text (Peer Review)
7. Bukti C-07 Penilaian Karya Ilmiah.pdf
Restricted to Registered users only

Download (783kB) | Request a copy
Official URL: http://ijpcr.com/volume8issue7/

Abstract

Background: Antiplatelet combination Aspirin (ASA) and Clopidogrel (CPG) has become part of therapeutic standard in patients with coronary artery disease (CAD). Thus, a decline in antiplatelet response due to platelet functional problem may be occured among CAD patients with diabetes mellitus (DM). Objective: To evaluate ASA platelet reactivity (Aspirin Reactivity Unit=ARU) and CPG (Platelet Reactivity Unit=PRU) among CAD patients with vs without DM who take a combination therapy of ASA 100 mg and CPG 75 mg/day. Methods: The study was done at Cardiology Outpatient Clinic – Dr. Soetomo Teaching Hospital Surabaya. A cross sectional observational study was carried out and an unpair qualitative analysis study was used to interprete the data. Platelet functional test was performed by VerifyNow, which was very specific for ASA (Aspirin Reactivity Unit = ARU) and CPG (Platelet Reactivity Unit = PRU). Results: A total of 20 patients were included in the study with the proportion of 10 CAD patients with DM and 10 CAD patients without DM. For ARU, about 4 CAD patients (40%) with DM and 3 CAD patients (30%) without DM seemed to have a resistance on ASA (p=1.000). For PRU, there were High On-Treatment Platelet Reactivity (HPR) on CAD patients with DM compared to CAD patients without DM (77.8% vs 11.1%; p = 0.015). Conclusion: Eventhough the number of CAD patient with DM who showed resistance to ASA was slightly higher compared to CAD patient without DM, there was no statistical difference between two groups. But for CPG, there were very significant higher HPR on CAD patient with DM than without DM.

Item Type: Article
Uncontrolled Keywords: Aspirin, Clopidogrel, Type 2 Diabetes Mellitus, Coronary Artery Disease, Platelet Reactivity
Subjects: R Medicine
R Medicine > RS Pharmacy and materia medica
R Medicine > RS Pharmacy and materia medica > RS1-441 Pharmacy and materia medica
Divisions: 05. Fakultas Farmasi > Farmasi Klinis
Peer Review
Creators:
CreatorsNIM/NIDN
Suharjonosuharjono@ff.unair.ac.id
Wahyudi E. D.UNSPECIFIED
Yunita A.UNSPECIFIED
Yogiarto M.UNSPECIFIED
Zulkarnain B. S.UNSPECIFIED
Depositing User: Mr M. Fuad Sofyan
Date Deposited: 24 Apr 2017 19:14
Last Modified: 24 Apr 2017 19:14
URI: http://repository.unair.ac.id/id/eprint/56674
Sosial Share:

Actions (login required)

View Item View Item